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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease
that slowly and progressively destroys the brain. In 1907, Alois
Alzheimer first described the symptoms as well as the
neuropathological features of Alzheimer's disease such as
plaques and tangles in the brain (1). The disease affects
memory and other cognitive abilities (e.g., thinking and
speaking, etc.), but it can also lead to other problems such as
confusion, changes of mood, and disorientation in time and
space. AD is the most common cause of cognitive impairment
in elderly, with an incidence that doubles every five years after
the age of 60 years (2). This disease affected approximately 24
million individuals worldwide in the year 2002 (3), 25 million
in the year 2005, and is expected to be over 80 million cases by
2040 (4). It is estimated to cost the world economy over $315
billion (5) and the U.S. economy $100 billion annually (6, 7).
The last decade has witnessed serious advances in the
clinical diagnosis and treatment of Alzheimer's disease, and
several professional organizations and workgroups have
developed consensus statements and guidelines for its’
diagnosis and treatment. Namely, the European Federation of
Neurological Societies (EFNS) has produced guidelines (8),
and Guidelines from the National Institute for Clinical
Excellence (NICE) (9), Guidelines of the German Society of
Neurology (10), Italian Guidelines (11), Canadian Guidelines
(12, 13), and British Guidelines (14) have been developed.
Despite the rapid increase in the knowledge of
epidemiology, genetics, risk factors and underlying
neuropathological mechanisms, there is no cure for AD yet. At
the same time, in comparison, little has been done concerning
the education of professionals on dementia and AD.
In one recent study (15), data on the education of European
neurologists on dementia were collected from 25 European
countries that were members of the European Federation of
Neurological Societies Scientific Panel on Dementia.
According to the results of this study, there was a gradual
decrease in teaching activity from medical school to specialty.
In most countries, the teaching of medical students about
dementia is obligatory, whereas there is no formal obligatory
education on dementia after graduation from medical schools.
Moreover, in half of the countries that participated in the study,
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obligatory dementia courses were part of training during the
specialty of neurology. Furthermore, based on published
European guidelines, national guidelines for dementia
management should be published in all countries. There is a
great need for education and training of all health professionals
worldwide in order to be able to diagnose and treat dementia.
The objectives of the present consensus statement are:
1. To describe, in detail, the situation of educational
programs about dementia in Europe in the years 2005 and 2008.
2. To propose rules and guidelines on the education of
professionals (neurologists, psychiatrists, primary care
providers, nurses, biologists, neuroradiologists, psychologists,
ergotherapists, physiotherapists, dentists) on the subject of
Alzheimer’s disease.
Previous efforts in reaching consensus
In 1997, a report on knowledge and attitudes about dementia
was organized by the European Medical Association in
collaboration with Pfizer Pharmaceuticals (16). With regard to
the key objectives of the research, doctors from ten European
countries responded as to: (a) the level of their knowledge
about dementia, (b) their attitudes towards the diagnosis of the
disease and its management/follow-up care, and (c) their
approach to the treatment of the disease. The conclusions of
this survey were:
1. The level of knowledge about dementia was variable with
general practitioners (GPs), and they asked for more theoretical
data on dementia along with information to help them in
diagnosing dementia.
2. GPs accepted that the care of patients with mental illness
should involve a close collaboration between themselves and
the patients, especially considering how long it takes.
3. hey realized that they have a pivotal role in the long-
term care/management of patients with dementia and that they
clearly need to be more knowledgeable about all the aspects of
dementia.
4. They perceived that they have a role in caring for the
family as well as the patient, and they welcomed any additional
information/resources that can be made available to them.
Another European Educational project for Professionals was
prepared by Janssen-Cilag (17). The purpose of this project was
to disseminate information about the different forms of
dementia including research, diagnosis, investigation,
meaningful activity and treatment options. The objectives of
this project were:
1. To improve the overall level of care of dementia patients.
2. To gain a better understanding of dementia nursing care
principles and of relations with confused people.
3. To understand what the care of people with dementia
means for staff.
4. To develop nursing care and employee training.
5. To redress deficiencies in further training in the field of
dementia.
6. To improve cooperation between professionals, relatives,
and institutions.
7. To pass on, exchange, and develop well-established tips
and tricks.
Methods
Our consensus building process began in 2005 (18, 19) and
was started by a simple questionnaire consisting of five
questions that were circulated to all EADC members asking:
1. Are there any relevant educational programs running in
their country, and if so, how could these be connected with the
consortium aim?
2. Who sponsors these programs?
3. Who teaches in these programs?
4. The contact details (name and e-mail) of one person from
each scientific team that would be responsible for collaborating
with the consortium regarding the preparation of our consensus
statement.
5. To check the information provided in the consensus
statement and correct any elements that in their opinion were
not correct.
Fourteen representatives of their countries answered to this
questionnaire. According to their responses, little had been
done at that time concerning professional training on dementia.
In most countries, there were no educational programs, or there
was little or no financial support, therefore a lot of action
should be taken in order for it to reach a satisfactory standard.
In particular, we would like to point out that France and the UK
were the only countries in 2005 where such training programs
existed, supported by the French and British Ministries of
Health, respectively. Unfortunately, in Italy and Switzerland,
which are countries with a tradition of medical and university
education, there was nothing reported to promote dementia
training, at least according to the contact persons that gave the
information.
At the beginning of 2008, another questionnaire, approved
by the members of the European Alzheimer Disease
Consortium (EADC), was distributed to different EADC
centers of the same European countries as in 2005, in order to
compare the current situation between the European countries.
The questionnaire consisted of more specific questions such as:
1. How many hours of dementia training in your University
are spent for medical students and during which year of their
education?
2. Which health professionals participate in this training?
3. How many hours did pharmaceutical companies spend
educating physicians during the last year?
4. How many hours do the scientific and family Alzheimer
associations spend educating physicians per year?
5. Is there any dementia teaching for doctors during their
specialty training? If so, how many hours?
Ten university professors participating in the EADC
responded to this questionnaire. Moreover, national
neurological, psychiatric, and Alzheimer societies and
associations were contacted. We also sent the same
questionnaire to pharmaceutical companies. Finally, following
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an extensive discussion among its members, the European
Alzheimer Disease Consortium prepared a consensus statement
about the current situation in Europe.
Results
The data collected from the European countries that
answered the 2008 questionnaire are presented below and in
Table 1.
Medical Students
Dementia training in medical students was present in all
countries that answered the questionnaire. Not all countries that
were contacted responded to our questionnaire. Medical school
consisted of six years in all countries that participated in the
study. The mean ± SD time spent for dementia training was
12.30±8.67 hours, and it ranged from 3 hours (in Switzerland
and Turkey) to 30 hours (in Sweden) (Figure 1).
Specialty Training
There is a great variation in the time spent for dementia
training and education during medical specialty training. Since
dementia is a multifactorial disease, its treatment is
multidisciplinary, and the medical specialties that are involved
are neurology, psychiatry, and geriatrics. In Holland, according
to the Nijmegen center, dementia training takes place only in
the specialty of geriatrics. It is interesting to note that the most
time for dementia training and education during specialty
(neurology, psychiatry, and geriatrics as mentioned above) is
spent in Switzerland (12 months), where the least amount of
time is spent for education of medical students. In two
countries, education on dementia during the above specialty
training is optional. In particular, in Finland, there is a six-
month optional training on dementia, and in Poland, there is no
specific dementia training but facultative meetings of about six
to eight hours.
Table 1
Dementia education for medical students and doctors during specialty training
COUNTRY PROGRAMS FOR MEDICAL TEACHERS HOURS PER YEAR SPENT ON
(EADC center) STUDENTS AND DOCTORS EDUCATION OF PHYSICIANS
DURING SPECIALTY TRAINING
1 Switzerland (Geneva) 3 hours for medical students and Doctors (specialty is not specified) One session of two hours each year from
12 mandatory months during specialty scientific associations
2 Holland (Maastricht) 8 hours theoretically, 4-8 hours during Old age psychiatrists, neurologists, No data
practical training for medical students. geriatricians
4 hours during specialty
3 Sweden (Stockholm) 30 hours during the second year for medical Physicians and other staff from the 30 hours from family associations.
students, for doctors during specialty varies dementia ward Not allowed from pharmaceutical
throughout the country companies
4 Finland (Kuopio) 10 hours for medical students, Neurologists and geriatricians 2 days/month from pharmaceutical
6 month training in dementia is suggested companies,
but not obligatory in specialty 1 day/month from scientific
associations,
1 week/month from family associations
5 Poland (Lodz) 15 hours during the sixth year of studies Psychiatrists and geriatricians 10 hours from pharmaceutical
for medical students, 6-8 hours for doctors companies,
during their specialty 20 hours from scientific associations,
none from family associations
6 Holland (Nijmegen) 13 hours for medical students, Neurologists, Geriatricians, 6 hours from pharmaceutical companies,
40 hours during geriatrics Psychiatrists, Nursing home medicine 8 hours from family and scientific
doctors associations
7 Germany 9 hours for medical students Professors (medical doctors) 30-100 hours from pharmaceutical
companies
8 Italy (Rome) 22 hours for medical students No data 6-8 hours from pharmaceutical
companies,
10-14 hours from scientific associations,
1 hour from family association
9 Turkey (Istanbul) 3 hours of lectures No data No formal education program from
Alzheimer Society, meetings from
pharmaceutical companies
10 Greece (Thessaloniki) 4 hours of lectures for medical students Neurologists and Psychiatrists Seminars and conferences organized by
Greek Association of Alzheimer’s
Disease, Neurological Society,
Psychiatric Society, General
Practitioner’s Society in cooperation
with pharmaceutical companies
Figure 1
Education and training on dementia in medical school
(in hours)
Dementia Educators
Since the medical specialties involved in dementia
management are neurology, psychiatry, and geriatrics, health
professionals that are responsible for dementia training are
doctors, in particular psychiatrists, neurologists, and
geriatricians. Neurologists do not participate in dementia
training in one country (Poland), whereas in Holland, according
to the answers of the Nijmegen center, nursing home doctors
are among the doctors responsible for training.
In Greece, a National Conference on Alzheimer’s disease
and Related Disorders has taken place every two years since
2000. During this conference, where more than 1000 health
professionals participate, several educational programs for
psychologists, social workers, physiotherapists, ergotherapists,
logotherapists, dentists, etc. are organized. Similar conferences
are organized in other countries as well.
Associations and pharmaceutical companies involved in
the education of physicians
In Finland, pharmaceutical companies and scientific and
family associations offer more time for the education of
physicians. On the other hand, in three of the countries that
responded, family Alzheimer associations are not actively
involved in the education of physicians, although in two of
them (Sweden and Germany) they are involved in the education
of the patients and their relatives (no data was included from
one center). Although pharmaceutical companies are involved
in dementia training in the majority of the countries that
participated in this consensus statement, but not any more in
Sweden, they did not provide us with information about their
educational programs.
From the data collected from European countries, it was
observed that in most of them, pharmaceutical companies and
scientific associations are responsible for the education of
health professionals on dementia in most of them. Only in
Sweden are pharmaceutical companies not allowed to perform
training on the area of dementia. Scientific associations are
involved in dementia education in 60% of the countries that
participated in this consensus statement. On the other hand, the
role of family associations in dementia training is reduced.
They participate in dementia training in less than half (40%) of
the countries studied. Therefore, the role of these associations
in organizing courses for dementia teaching and training should
be enhanced.
Discussion
Everybody who provides care for patients with Alzheimer’s
disease or their families should be able to receive formal
education and professional training. All care providers
including (a) physicians, (b) nurses, (c) social workers, (d)
support group leaders, and (e) biologists who are involved in
the diagnosis and treatment of Alzheimer’s disease should be
adequately trained, especially neurologists, who should be the
most involved in the diagnosis and management of dementia.
Also, training on dementia must be included in the curriculum
of medical schools, taking into consideration that it is a disease
affecting millions of elderly people worldwide, and its
prevalence is continuously growing over the years. Moreover,
dementia training should be included as compulsory in
neurology and geriatric specialty training. Experts in the field
of dementia should be responsible for this training.
It seems that professional training on dementia has been
greatly developed recently, in contrast to what was recorded in
our previous study (18) three years ago, in which some
countries were reported not to have any type of dementia
training. However, along with the observation that there were
different answers from centers in the same country, this
difference might be due to the fact that the training programs
vary, and there is no standard dementia training in each
country. Therefore, the results we had in each study varied
according to the university that responded to the questionnaire.
In the countries that participated in our consensus statement,
such training programs are provided for medical students
during their studies and doctors during their specialty training.
Compared to the study of Hasselbalch et al., (15) no
progressive decrease in teaching activities from undergraduate
to postgraduate studies was observed in our study. Moreover,
our consensus includes the role of the pharmaceutical
companies in the education of physicians on dementia and the
hours spent on dementia training for medical students and
doctors during specialty training (in the university, from
pharmaceutical companies, and scientific associations).
Pharmaceutical companies and scientific associations play a
major role in preparing such programs. In Poland,
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pharmaceutical companies have prepared such educational
projects. In Finland, the organizations that are coordinating
training in dementia are Finnish Alzheimer Research and the
Finnish Alzheimer Association. In Greece, universities and
scientific associations (neurological, psychiatric, Association of
Alzheimer Disease and Related Disorders) have the main role
in the education sponsored mainly by pharmaceutical
companies (Novartis, Pfizer, Janssen, Lundbeck).
Education and training of doctors on dementia should take
place at all stages (medical school, during specialty, after
specialty). Moreover, dementia training for care providers must
include instruction in several relevant dimensions. Emphasis
should be given in the areas of early detection and diagnosis of
dementia, e.g., through the most recent neuroimaging
techniques (MRI, PET, SPECT, fMRI), CSF biomarkers, and
electrophysiological methods (EEG, ERPs). Moreover, there
should be a continuous update of information and knowledge
on new methods and research being performed for the
pharmacological and non-pharmacological treatment of
Alzheimer’s disease. What is also very important is the
development of a very good, friendly, and trusting relationship
between the patient and the health care provider, therefore
specific attention should be given in the development of
communication with the patient and elements such as respect,
support, compassion, and humor. The trainers should be at a
Master's level or above, professionals with well-known
scientific status and expertise in the field of aging and dementia
care. After the end of the professional training, each participant
should receive a certificate of completion. Useful information
like telephone numbers of local support services, contact
information for dementia care specialists, and web page
addresses containing information on dementing diseases,
should be provided for free for anybody, either patient,
caregiver, or health professional. After the French initiative for
dementia to be a European Priority, we suggest development of
a European Educational Program, which could run in all
European countries.
National Alzheimer’s associations and other scientific
associations all over the world need to encourage their
respective governments to train more health professionals in all
areas of dementia care. Each government, and also
pharmaceutical companies and local scientific associations
should support and fund the development of dementia care
training and research centers. Furthermore, conferences and
seminars should be held and supported by all associations
mentioned above, regarding all aspects of AD. These
conferences and seminars should be open both to health
professionals and caregivers. These actions could give a great
stimulus to the diagnosis and treatment of AD.
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